Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
GRI Bio ( (GRI) ) has shared an announcement.
On December 12, 2025, GRI Bio announced the closing of an $8.0 million public offering of common stock and Series F warrants, with H.C. Wainwright & Co. as the exclusive placement agent. The proceeds will support product development and corporate purposes, potentially impacting the company’s market position and operations by enhancing its financial resources.
The most recent analyst rating on (GRI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
GRI Bio’s stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
GRI Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory, fibrotic, and autoimmune diseases. The company targets Natural Killer T (NKT) cells to interrupt disease progression and restore immune system balance, with a lead program aimed at treating idiopathic pulmonary fibrosis.
Average Trading Volume: 554,632
Technical Sentiment Signal: Sell
Current Market Cap: $3.96M
Learn more about GRI stock on TipRanks’ Stock Analysis page.